REG - ValiRx PLC - Issue of Share Options

ValiRxAnnouncement

18/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221018:nRSR1613Da&default-theme=true

RNS Number : 1613D  ValiRx PLC  18 October 2022

18 October 2022

 

ValiRx PLC ("ValiRx" or the "Company")

 

Issue of Share Options

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health announces today the grant
of a share option under the Company share option scheme.

A share option over 150,000 ordinary shares has been granted to Stella Panu in
recognition of her recent appointment as Non-executive Director of the
Company.

The structure of the share option is identical to the share options scheme
announced on 6 September 2022.

The options detailed in the schedule below are exercisable only under market
conditions that demonstrate growth in the Company's market capitalisation.
Band 1 options vest only after the Company's share price has maintained a 20
Day VWAP (Volume Weighted Average Price) of 25p, Band 2 options vest only
after the share price has maintained a 20 Day VWAP of 30p and Band 3 Options
vest only after the share price has maintained a 20 Day VWAP of 40p within 2
years of the options being issued.  If the price has not reached these price
targets by 11 October 2024, the options will lapse; if they meet the criteria,
the options can be exercised at any date to 11 October 2032 with an exercise
price of 12p.

Directors:

              Band 1 Options  Band 2 Options  Band 3 Options
 Stella Panu  -               75,000          75,000

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

*** ENDS ***

 

For more information, please contact:

 

 ValiRx plc                                            Tel: +44 (0) 2476 796496

                                                       www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                                 Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 Dr Adam Hargreaves, Shareholder Representative        Adam.Hargreaves@pathcelerate.com (mailto:Adam.Hargreaves@pathcelerate.com)

 V Formation (Public Relations)                        +44 (0) 115 787 0206

                                                       www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                                   lucy@vformation.biz

                                                       sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)      Tel: +44 (0) 20 7213 088

 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities Limited (Joint Broker)              Tel: +44 (0) 20 7397 8900

 Russell Kerr / Michael Johnson (Sales)

 Callum Davidson / Giles Balleny (Corporate Finance)
 Turner Pope Investments (Joint Broker)                Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's
health to improve patient lives. We provide the scientific, financial and
commercial framework towards enabling rapid translation of innovative science
into clinical development.

With our extensive and proven experience in research and drug development, we
select and incubate promising novel drug candidates and guide them through an
optimised process of development, from pre-clinical studies to clinic and
investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial
domains, with the aim of achieving a more streamlined, less costly, drug
development process.  We work closely with our selected collaborators and
leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation. https://www.valirx.com/ (https://www.valirx.com/)

The Company listed on the AIM Market of the London Stock Exchange in October
2006 and trades under the ticker symbol: VAL.

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Stella Panu

 
 2   Reason for notification
 a.  Position/Status                                              Director

 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         ValiRx PLC
 b.  LEI                                                          213800VQKB9SJCQDET40
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Option over new ordinary shares

Identification Code

 b.  Nature of the transaction                                    Issue of Band 2 Options
 c.  Price(s) and volume(s)
                                                                              Price(s)    Volume(s)
     12p                                                                                              75,000

 d.  Aggregated information

     - Aggregated Volume                                          N/A

     - Price
 e.  Date of the transaction                                      17/10/2022
 f.  Place of the transaction                                     London, UK

 

2

Reason for notification

a.

Position/Status

Director

 

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a.

Name

ValiRx PLC

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Option over new ordinary shares

 

 

b.

Nature of the transaction

Issue of Band 2 Options

c.

Price(s) and volume(s)

Price(s)

Volume(s)

 12p

 75,000

d.

Aggregated information

- Aggregated Volume

- Price

 

N/A

 

e.

Date of the transaction

 17/10/2022

f.

Place of the transaction

London, UK

 

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1                   Details of the person discharging managerial responsibilities/person closely
                     associated
 a.                  Name                                                         Stella Panu
 2                   Reason for notification
 a.                  Position/Status                                              Director

 b.                  Initial notification/                                        Initial notification

                     Amendment
 3                   Details of the issuer, emission allowance market participant, auction
                     platform, auctioneer or auction monitor
 a.                  Name                                                         ValiRx PLC
 b.                  LEI                                                          213800VQKB9SJCQDET40

 
 4                   Details of the transaction(s): section to be repeated for (i) each type of
                     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                     place where transactions have been conducted
 a.                  Description of the financial instrument, type of instrument  Option over new ordinary shares

Identification Code

                                                                                   ISIN: GB00BLH13C52
 b.                  Nature of the transaction                                    Issue of Band 3 Options
 c.                  Price(s) and volume(s)
                     Price(s)                                                                                                 Volume(s)
                                                                                             12p        75,000

 d.                  Aggregated information

                     - Aggregated Volume                                          N/A

                     - Price
 e.                  Date of the transaction                                      17/10/2022
 f.                  Place of the transaction                                     London, UK

2

Reason for notification

a.

Position/Status

Director

 

 

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a.

Name

ValiRx PLC

b.

LEI

   213800VQKB9SJCQDET40

 

4

Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Option over new ordinary shares

 

 ISIN: GB00BLH13C52

b.

Nature of the transaction

Issue of Band 3 Options

c.

Price(s) and volume(s)

Price(s)

Volume(s)

 

 12p

 75,000

d.

Aggregated information

- Aggregated Volume

- Price

 

N/A

e.

Date of the transaction

 17/10/2022

f.

Place of the transaction

London, UK

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBKOBPPBDDDKD